思瑞浦(688536.SH):公司在蘇州的自有測試廠建設順利推進中,將在2023年年底前後投入試運營
格隆匯11月23日丨思瑞浦(688536.SH)近日接受特定對象調研時表示,公司夯實產品設計能力的同時,也在不斷加強國產供應鏈建設。在晶圓方面,公司致力於打造國內與海外雙循環的晶圓供應體系,為國內業務的持續發展及海外業務拓展提供堅實的供應鏈保障。公司目前在與多家國產晶圓廠合作,相關國產產線建設順利推進中,未來國內產能將逐步開始釋放。此外,在自有測試能力建設方面,公司在蘇州的自有測試廠建設順利推進中,將在2023年年底前後投入試運營。蘇州測試廠的建設也將在一定程度上增強公司測試產能的自主性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.